検索
Novo Nordisk A/S
NVOウォッチリストに追加
46.600USD
-0.910-1.92%
終値 09-04 16:00（ET）
156.20B時価総額
10.91直近12ヶ月PER
詳細情報 Novo Nordisk A/S 企業名
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Novo Nordisk A/S プロフィール
企業コードNVO
会社名Novo Nordisk A/S
上場日May 17, 1974
最高経営責任者「CEO」Doustdar (Maziar Mike)
従業員数76302
証券種類Depository Receipt
決算期末May 17
本社所在地Novo Alle 1
都市BAGSVAERD
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国Denmark
郵便番号2880
電話番号4544448888
ウェブサイトhttps://www.novonordisk.com/
企業コードNVO
上場日May 17, 1974
最高経営責任者「CEO」Doustdar (Maziar Mike)
Novo Nordisk A/Sの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Desiree Jantzen Asgreen
Ms. Desiree Jantzen Asgreen
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Helena Saxon
Ms. Helena Saxon
Independent Director
Independent Director
--
--
Dr. Jan van de Winkel, Ph.D.
Dr. Jan van de Winkel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Ludovic Helfgott
Mr. Ludovic Helfgott
Executive Vice President - Product and Portfolio Strategy
Executive Vice President - Product and Portfolio Strategy
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Desiree Jantzen Asgreen
Ms. Desiree Jantzen Asgreen
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Helena Saxon
Ms. Helena Saxon
Independent Director
Independent Director
--
--
Dr. Jan van de Winkel, Ph.D.
Dr. Jan van de Winkel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
よくある質問
Novo Nordisk A/Sの上位5名の株主は誰ですか？
Novo Nordisk A/Sの上位5名の株主は以下のとおりです。Ms. Desiree Jantzen Asgreen
Novo Nordisk A/S（NVO）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Novo Nordisk A/Sの株式を保有している機関は2975社あり、保有株式の総市場価値は約332.82Mで、全体の9.89%を占めています。2025Q4と比較して、機関の持ち株は-2714627.00増加しています。
Novo Nordisk A/Sの最大の収益源は何ですか？
2026Q1において、Total GLP-1部門がNovo Nordisk A/Sにとって最大の収益を生み出しており、その金額は5.72Bで、全収益の46.87%を占めています。